Strides Arcolab has received an approval from the United States Food & Drug Administration (USFDA) for Tacrolimus Capsules USP, 0.5 mg, 1 mg, and 5 mg. The US market for generic Tacrolimus is approximately $676 million, according to IMS data as on September 2013.
The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed directly by Strides in the US market.
Tacrolimus capsule is an immunosuppressant used for preventing organ rejection in certain patients following liver, kidney, or heart transplant. It may be used along with other medicines.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
